BRAF and thyroid cancer: The characterization of molecular variants and fusions as BRAF-like, RAS-like, and non-BRAF non-RAS-like has helped to group molecular alterations in thyroid cancer that share similar risk of events such as extra-thyroidal extension and lymph node metastases (71, 72).